IN THE midst of recovery from the devastating effects of the Covid pandemic, whispers of a potential new viral threat have surfaced, capturing the attention of global health experts and citizens alike. Human metapneumovirus, a respiratory pathogen that has largely flown under the radar, is now being dubbed the potential ‘Covid 2.0.’ But is this comparison justified, and what should we learn from the last three years to prepare for any future pandemic?
Ìý
Rise of HMPV
This is not a new virus. Discovered in 2001, it belongs to the same viral family as respiratory syncytial virus and is a leading cause of respiratory illness in children, the elderly, and immunocompromised individuals. Unlike SARS-CoV-2, the virus that causes Covid-19, HMPV has not been associated with global pandemics. However, recent surges in cases, coupled with its ability to cause severe respiratory distress, have raised alarms among virologists and epidemiologists.
In some regions, it has accounted for up to 20 per cent of respiratory infections requiring hospitalisation. With symptoms like coughing, fever, nasal congestion, and shortness of breath, the virus mimics many aspects of influenza and Covid-19, complicating diagnosis and treatment. What differentiates HMPV from seasonal viruses is its ability to evade immunity, potentially leading to widespread outbreaks if left unchecked.
Ìý
Lessons from Covid-19
COVID-19 has taught hard lessons about the vulnerabilities of healthcare systems, the importance of global cooperation, and the devastating consequences of delayed action. As we examine the potential threat of HMPV, these lessons become our greatest asset.
Surveillance is key. Early detection and monitoring of viral outbreaks are essential to preventing pandemics. The lack of robust surveillance systems in the early days of Covid allowed the virus to spread undetected. With HMPV, enhanced surveillance could involve genetic sequencing, rapid diagnostic tools, and integrating real-time data from hospitals and clinics.
Investing in research is crucial. One of the triumphs of the Covid-19 era was the rapid development of vaccines. However, such success requires sustained investment in virology and immunology research. Currently, there is no approved vaccine or specific antiviral treatment for HMPV. Funding research now could save millions of lives later.
Public health communication matters. Misinformation plagued Covid-19 management, from vaccine hesitancy to mask resistance. Clear, science-based communication about the risks of HMPV and the measures to mitigate its spread is critical. This includes combating myths and ensuring that accurate information reaches the public through trusted channels.
Ìý
Climate change and urbanisation
THE emergence and re-emergence of infectious diseases like HMPV are increasingly linked to global phenomena like climate change and urbanisation. Rising temperatures and shifting ecosystems are driving humans and animals closer together, increasing the likelihood of zoonotic spillovers. Densely populated cities amplify the speed at which viruses spread, as seen during the Covid-19 pandemic.
For HMPV, this means a heightened risk of outbreaks in vulnerable populations. Urban settings with poor air quality exacerbate respiratory illnesses, making individuals more susceptible to severe outcomes. Addressing these root causes requires international collaboration to tackle climate change and improve urban planning.
Another lesson from Covid-19 is that pandemics are not merely health crises — they are societal disruptions. The economic toll of Covid-19 was unprecedented, with millions losing jobs and industries like travel and hospitality brought to their knees. HMPV could have a similar ripple effect if it reaches pandemic levels, underscoring the need for preemptive planning.
Policymakers must prioritise building resilient economies capable of weathering such shocks. This includes strengthening supply chains, ensuring equitable access to medical resources, and supporting small businesses that often bear the brunt of economic downturns.
Ìý
Ethical considerations
THE inequities highlighted during the Covid-19 pandemic — from vaccine distribution to healthcare access — must not be repeated. If HMPV emerges as a global threat, ensuring equitable distribution of resources will be paramount. This involves supporting low- and middle-income countries with funding, technology transfer, and logistical support to manage outbreaks effectively.
Ìý
Path forward
While it is premature to label HMPV as ‘Covid 2.0,’ the comparison serves as a wake-up call. Our interconnected world is more vulnerable to pandemics than ever before, and complacency is not an option. Preparing for future viral threats requires a multifaceted approach.
Strengthening global health infrastructure is vital. Global health organisations like the World Health Organisation must be empowered with resources and authority to coordinate responses to emerging threats. National governments should collaborate to standardise protocols for outbreak detection and containment.
Promoting vaccine development is essential. Accelerating the timeline for vaccine development and approval through public-private partnerships and international collaboration is crucial. Advanced platforms like mRNA technology, which proved effective against Covid-19, should be leveraged for HMPV.
Fostering a culture of preparedness is critical. Pandemics should no longer be treated as once-in-a-century events. Routine drills, public education campaigns, and robust supply chain management can ensure societies are better prepared for future outbreaks.
Ìý
Call to action
COVID-19 revealed humanity’s resilience and ingenuity, but it also exposed deep flaws in preparedness and response systems. As HMPV garners attention, it is crucial to approach the threat with vigilance and proactivity. Whether or not it evolves into a pandemic, the steps taken today will determine the capacity to handle future public health crises. By investing in science, fostering global cooperation, and learning from the past, a safer, healthier world can be built. The response to HMPV must be swift, inclusive, and grounded in evidence. It is a reminder that vigilance against infectious diseases is a continuous process, one that demands not only resources but also the collective will to act. The scars of Covid-19 must serve as a roadmap to prevent the next pandemic from wreaking havoc on lives and livelihoods.
Ìý
Mahmodul Shesheir is an associate researcher at Yale University, Mehadi Shawon is a PhD student at Kansas State University and Faiaz Ahmed is a research coordinator at Yale University.
